Contributions
Abstract: P1030
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: In multiple sclerosis (MS), motor dysfunction is frequent and has been associated with spinal cord (SC) atrophy. However, specific changes in daily activity (DA) and their relation with SC damage remain unexplored.
Objective: To characterize the profile of DA parameters measured by an accelerometer and to explore their relationship with cervical SC area and volume.
Methods: We included 80 patients and 26 healthy volunteers (HV) who wore an accelerometer for 7 days to measure average DA (counts per day) and sedentary, light and moderate to vigorous physical activity [MVPA] (counts per minute). All participants underwent a SC MRI with 3D-MPRAGE and we measured the upper cervical cross-sectional area (UCCA, at C2-C3 level in mm2) and volume (C1 to C3 in mm3). 41 patients underwent a PSIR sequence to measure the upper cord grey matter area (UCGA, at C2-C3 level in mm2) but 3 were excluded due to low-quality scans and 11 due to grey matter lesions. Patients were evaluated with the expanded disability status scale (EDSS) and classified based on their walking ability: EDSS < 4.0 (N=67) and >4.0 (N=13).
Results. Patients had less DA compared to HV (mean [standard deviation] = 500165.9 [194503.3] vs 610694.6 [203748.1]; p=0.02); lower MVPA (mean [SD]= 36.5 [27.8] vs 66.1 [33.3]; p< 0.001), lower UCCA (mean [SD]=48.4 [7] vs 51.9 [5.1]; p=0.02) and SC volume (mean [SD]=941 [216.9] vs 1030.1 [162.9]; p=0.04). Patients with >4.0 showed less DA compared to patients with EDSS < 4.0 (mean [SD]= 323136.2 [134070.4] vs 534515 [186130]; p< 0.001), less MVPA (mean [SD]= 12.8 [18.3] vs 41.1 [27.1]; p< 0.001), higher sedentary activity (mean [SD]= 1227.4 [73.2] vs 1135.3 [119.9]; p=0.001), lower UCCA (mean [SD]= 43.7 [5.5] vs 49.3 [6.9]; p=0.006) and lower SC volume (mean [SD]= 796.1 [158.2] vs 969 [216.5]; p=0.004). No differences were observed in UCGA between EDSS subgroups.
UCCA and SC volume correlated with DA (r=0.3, p=0.03), and UCGA with DA (r=0.5, p=0.009) and MVPA (r=0.4, p=0.03). Only UCGA showed a moderate association with average DA (r=0.6, p=0.005), light activity (r=0.4, p=0.048) and MVPA (r=0.5, p=0.02) when controlling for age and sex.
Conclusion. As walking disability progresses in MS, patients become more sedentary and carry out less vigorous activities. Our study provides further evidence that SC atrophy in MS, and especially grey matter impacts negatively in daily activity, and mainly in highly demanding activities.
Disclosure: This work was funded by a Proyecto de Investigacion en Salud (FIS 2015. PI15/00587, S.L., A.S.) integrated in the Plan Estatal de Investigación Científica y Técnica de Innovación I+D+I and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER, 'Otra manera de hacer Europa'); Red Española de Esclerosis Múltiple (REEM) (RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02).
NSV receives funding from the Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER) (FI16/00251), Predoctoral Grant for Health Research (PFIS).
EMH and JA declare nothing to disclose.
ES has received travel reimbursement from TEVA
MS received speaker honoraria from Genzyme and Novartis, and funding from the Generalitat de Catalunya (SLT002/16/00354).
EML received speaking honoraria from Biogen, Genzyme and Novartis, travel reimbursement from Roche, Sanofi-Genzyme and TEVA, and funding from the Spanish Government (Instituto de Salud Carlos III (CM13/00150; MV15/00012; JR16/00006), Fundació Marató TV3 (20142030), GMSI (2016) and Fundació Cellex Barcelona
YB: received speaking honoraria from Biogen, Novartis and Genzyme.
AS received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA and Novartis, and funding from the Spanish Government (PI15/00587, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02),
SL received speaker honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck, and research support from a Juan Rodes grant from the Instituto de Salud Carlos III (JR14/00016) and the Spanish Government (PI15/00587).
Abstract: P1030
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: In multiple sclerosis (MS), motor dysfunction is frequent and has been associated with spinal cord (SC) atrophy. However, specific changes in daily activity (DA) and their relation with SC damage remain unexplored.
Objective: To characterize the profile of DA parameters measured by an accelerometer and to explore their relationship with cervical SC area and volume.
Methods: We included 80 patients and 26 healthy volunteers (HV) who wore an accelerometer for 7 days to measure average DA (counts per day) and sedentary, light and moderate to vigorous physical activity [MVPA] (counts per minute). All participants underwent a SC MRI with 3D-MPRAGE and we measured the upper cervical cross-sectional area (UCCA, at C2-C3 level in mm2) and volume (C1 to C3 in mm3). 41 patients underwent a PSIR sequence to measure the upper cord grey matter area (UCGA, at C2-C3 level in mm2) but 3 were excluded due to low-quality scans and 11 due to grey matter lesions. Patients were evaluated with the expanded disability status scale (EDSS) and classified based on their walking ability: EDSS < 4.0 (N=67) and >4.0 (N=13).
Results. Patients had less DA compared to HV (mean [standard deviation] = 500165.9 [194503.3] vs 610694.6 [203748.1]; p=0.02); lower MVPA (mean [SD]= 36.5 [27.8] vs 66.1 [33.3]; p< 0.001), lower UCCA (mean [SD]=48.4 [7] vs 51.9 [5.1]; p=0.02) and SC volume (mean [SD]=941 [216.9] vs 1030.1 [162.9]; p=0.04). Patients with >4.0 showed less DA compared to patients with EDSS < 4.0 (mean [SD]= 323136.2 [134070.4] vs 534515 [186130]; p< 0.001), less MVPA (mean [SD]= 12.8 [18.3] vs 41.1 [27.1]; p< 0.001), higher sedentary activity (mean [SD]= 1227.4 [73.2] vs 1135.3 [119.9]; p=0.001), lower UCCA (mean [SD]= 43.7 [5.5] vs 49.3 [6.9]; p=0.006) and lower SC volume (mean [SD]= 796.1 [158.2] vs 969 [216.5]; p=0.004). No differences were observed in UCGA between EDSS subgroups.
UCCA and SC volume correlated with DA (r=0.3, p=0.03), and UCGA with DA (r=0.5, p=0.009) and MVPA (r=0.4, p=0.03). Only UCGA showed a moderate association with average DA (r=0.6, p=0.005), light activity (r=0.4, p=0.048) and MVPA (r=0.5, p=0.02) when controlling for age and sex.
Conclusion. As walking disability progresses in MS, patients become more sedentary and carry out less vigorous activities. Our study provides further evidence that SC atrophy in MS, and especially grey matter impacts negatively in daily activity, and mainly in highly demanding activities.
Disclosure: This work was funded by a Proyecto de Investigacion en Salud (FIS 2015. PI15/00587, S.L., A.S.) integrated in the Plan Estatal de Investigación Científica y Técnica de Innovación I+D+I and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER, 'Otra manera de hacer Europa'); Red Española de Esclerosis Múltiple (REEM) (RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02).
NSV receives funding from the Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER) (FI16/00251), Predoctoral Grant for Health Research (PFIS).
EMH and JA declare nothing to disclose.
ES has received travel reimbursement from TEVA
MS received speaker honoraria from Genzyme and Novartis, and funding from the Generalitat de Catalunya (SLT002/16/00354).
EML received speaking honoraria from Biogen, Genzyme and Novartis, travel reimbursement from Roche, Sanofi-Genzyme and TEVA, and funding from the Spanish Government (Instituto de Salud Carlos III (CM13/00150; MV15/00012; JR16/00006), Fundació Marató TV3 (20142030), GMSI (2016) and Fundació Cellex Barcelona
YB: received speaking honoraria from Biogen, Novartis and Genzyme.
AS received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA and Novartis, and funding from the Spanish Government (PI15/00587, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02),
SL received speaker honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck, and research support from a Juan Rodes grant from the Instituto de Salud Carlos III (JR14/00016) and the Spanish Government (PI15/00587).